【レポートの概要（一部）】
1 Table of Contents
1 Table of Contents 10
1.1 List of Tables 17
1.2 List of Figures 22
2 Introduction 24
2.1 Catalyst 24
2.2 Related Reports 25
2.3 Upcoming Related Reports 25
3 Disease Overview 26
3.1 Etiology and Pathophysiology 26
3.1.1 Etiology 26
3.1.2 Pathophysiology 28
3.2 Prognosis 29
3.3 Quality of Life 29
3.4 Symptoms 30
4 Epidemiology 31
4.1 Risk Factors and Comorbidities 31
4.1.1 Women are at a higher risk of developing SLE than men 32
4.1.2 Caucasians are at lower risk of developing SLE than other ethnicities 32
4.1.3 Familial history has been associated with an increased risk of developing SLE 34
4.1.4 Certain occupational and environmental exposures trigger SLE 34
4.2 Global Trends 36
4.2.1 US 36
4.2.2 5EU 37
4.2.3 Japan 40
4.3 Forecast Methodology 41
4.4 Sources Used 44
4.4.1 US 44
4.4.2 France 45
4.4.3 Germany 45
4.4.4 Italy 45
4.4.5 Spain 46
4.4.6 UK 47
4.4.7 Japan 48
4.5 Sources Not Used 49
4.5.1 US 49
4.5.2 5EU 49
4.5.3 Japan 50
4.6 Forecast Assumptions and Methods 50
4.6.1 US 51
4.6.2 5EU 51
4.6.3 Japan 55
4.7 Epidemiological Forecast of SLE (2012-2022) 56
4.7.1 Diagnosed Prevalent Cases of SLE 56
4.7.2 Age-Specific Prevalent Cases of SLE 58
4.7.3 Sex-Specific Prevalent Cases of Diagnosed SLE 60
4.7.4 Age-Standardized Prevalence of SLE 62
4.7.5 Diagnosed Prevalent Cases of LN 63
4.7.6 Prevalent Cases of LN, Segmented by Class 65
4.8 Discussion 67
4.8.1 Conclusions on Epidemiology Trends 67
4.8.2 Limitations of the Analysis 68
4.8.3 Strengths of the Analysis 69
5 Disease Management 71
5.1 Diagnosis Overview 71
5.1.1 SLE Diagnosis 71
5.1.2 LN Diagnosis 74
5.2 Treatment Overview 76
5.3 US 80
5.3.1 Diagnosis 80
5.3.2 Clinical Practice 81
5.4 France 83
5.4.1 Diagnosis 83
5.4.2 Clinical Practice 83
5.5 Germany 85
5.5.1 Diagnosis 85
5.5.2 Clinical Practice 85
5.6 Italy 87
5.6.1 Diagnosis 87
5.6.2 Clinical Practice 87
5.7 Spain 89
5.7.1 Diagnosis 89
5.7.2 Clinical Practice 89
5.8 UK 91
5.8.1 Diagnosis 91
5.8.2 Clinical Practice 91
5.9 Japan 93
5.9.1 Diagnosis 93
5.9.2 Clinical Practice 93
6 Competitive Assessment 95
6.1 Overview 95
6.2 Strategic Competitor Assessment 96
6.3 Product Profiles – Major Brands 97
6.3.1 Antimalarial Therapy (numerous brand names) 97
6.3.2 Steroids (numerous brand names) 102
6.3.3 Methotrexate (numerous brand names) 108
6.3.4 Mycophenolate Mofetil (numerous brand names) 113
6.3.5 Cyclophosphamide (numerous brand names) 118
6.3.6 Azathioprine (numerous brand names) 123
6.3.7 Calcineurin Inhibitors (numerous brand names) 127
6.3.8 Benlysta (belimumab) 132
6.3.9 Rituxan (rituximab) 141
6.3.10 Minor Therapeutic Classes 146
7 Opportunity and Unmet Need 147
7.1 Overview 147
7.2 Unmet Needs 148
7.2.1 Efficacious Treatments with Reduced Side Effects 148
7.2.2 Management of LN 150
7.2.3 Improvement in Patients’ Mortality 151
7.2.4 Management of Lupus Comorbidities 151
7.2.5 Sensitive and Reliable Biomarkers 152
7.2.6 Physicians’ Education and Public Awareness of SLE 153
7.2.7 Unmet Needs Gap Analysis 153
7.3 Opportunities 154
7.3.1 Efficacious and Safe Therapies 154
7.3.2 Therapies Targeting LN Patients 155
7.3.3 Treatments for Common Lupus Comorbidities 156
7.3.4 Discovery of Biomarkers 156
8 Pipeline Assessment 157
8.1 Overview 157
8.2 Clinical Trial Mapping 158
8.2.1 Clinical Trials by Country 158
8.2.2 Clinical Trials by Phase and Trial Status 159
8.3 Promising Drugs in Clinical Development 161
8.3.1 Blisibimod (A-623) 164
8.3.2 Tabalumab (LY-2127399) 171
8.3.3 Atacicept 178
8.3.4 Epratuzumab 184
8.3.5 Lupuzor (rigerimod) 192
8.3.6 Orencia (abatacept) 198
9 Current and Future Players 205
9.1 Overview 205
9.2 Trends in Corporate Strategy 207
9.3 Company Profiles 209
9.3.1 GlaxoSmithKline 209
9.3.2 Roche 211
9.3.3 UCB 214
9.3.4 Eli Lilly and Company 216
9.3.5 Bristol-Myers Squibb 218
9.3.6 Anthera Pharmaceuticals 219
9.3.7 ImmuPharma 221
9.3.8 Merck Serono 222
10 Market Outlook 224
10.1 Global Markets 224
10.1.1 Forecast 224
10.1.2 Drivers and Barriers – Global Issues 231
10.2 US 234
10.2.1 Forecast 234
10.2.2 Key Events 238
10.2.3 Drivers and Barriers 238
10.3 France 241
10.3.1 Forecast 241
10.3.2 Key Events 245
10.3.3 Drivers and Barriers 245
10.4 Germany 247
10.4.1 Forecast 247
10.4.2 Key Events 251
10.4.3 Drivers and Barriers 251
10.5 Italy 253
10.5.1 Forecast 253
10.5.2 Key Events 257
10.5.3 Drivers and Barriers 257
10.6 Spain 259
10.6.1 Forecast 259
10.6.2 Key Events 263
10.6.3 Drivers and Barriers 263
10.7 UK 265
10.7.1 Forecast 265
10.7.2 Key Events 269
10.7.3 Drivers and Barriers 269
10.8 Japan 271
10.8.1 Forecast 271
10.8.2 Key Events 275
10.8.3 Drivers and Barriers 275
11 Appendix 278
11.1 Bibliography 278
11.2 Abbreviations 293
11.3 Methodology 298
11.4 Forecasting Methodology 298
11.4.1 Diagnosed SLE and LN Patients 298
11.4.2 Percent Drug-Treated Patients 299
11.4.3 Drugs Included in Each Therapeutic Class 299
11.4.4 Launch and Patent Expiry Dates 299
11.4.5 General Pricing Assumptions 300
11.4.6 Individual Drug Assumptions 301
11.4.7 Generic Erosion 304
11.4.8 Pricing of Pipeline Agents 305
11.5 Physicians and Specialists Included in this Study 306
11.6 Primary Research – Prescriber Survey 308
11.7 About the Authors 309
11.7.1 Analysts 309
11.7.2 Epidemiologist 310
11.7.3 Global Head of Healthcare 310
11.8 About GlobalData 311
11.9 Disclaimer 311
【レポート販売概要】
■ タイトル：全身性エリテマトーデス及びループス腎炎：世界市場（医薬品市場予測及び分析～2022）■ 英文：PharmaPoint: Systemic Lupus Erythematosus and Lupus Nephritis - Global Drug Forecast and Market Analysis to 2022
■ 発行日：2013年10月31日
■ 調査会社：GlobalData
■ 商品コード：GDATA403162576
■ 調査対象地域：グローバル
- 強直性脊椎炎の疫学的予測EpiCast Report: Ankylosing Spondylitis - Epidemiology Forecast to 2024 Summary Ankylosing spondylitis (AS) - a systemic, chronic, and progressive inflammatory arthritis, is the prototype of a family of related disorders known as seronegative spondyloarthritis (SpA) and one of the most common rheumatic diseases across the globe. AS primarily affects the spine and sacroiliac (SI) joints and progress …
- 宇宙航空用DC-DCコンバータの世界市場予測（～2020）The DC-DC converters market for space is projected to grow from USD 213.2 Million in 2015 to USD 268.2 Million by 2020, at a CAGR of 4.70% from 2015 to 2020. Factors influencing the growth of this market include rise in the number of satellite constellations in the world by different countries, emergence of new power architecture and emergence of digital power management and control. The space pow …
- 世界の心血管手術機器開発動向：医療機器パイプライン分析2015Cardiovascular Surgery Devices - Medical Devices Pipeline Assessment, 2015 Summary GlobalData's Medical Devices sector report, “Cardiovascular Surgery Devices - Medical Devices Pipeline Assessment, 2015" provides an overview of Cardiovascular Surgery Devices currently in pipeline stage. The report provides comprehensive information on the pipeline products with comparative analysis of the products …
- 古紙処理サービス/装置の世界市場The global market for waste paper management has been growing proportionally with the increasing environmental concerns among people and enforcement of stringent environmental laws & regulations. The paper industry has been dominated by North America for more than a century now. North America is the largest producer as well as consumer of paper & paper products with a yearly per capita consumption …
- POC検査装置の世界市場：企業動向Point of Care Diagnostics - Current and Future Players Summary The Point-Of-Care (POC) market is very fragmented with over 100 players currently marketing POC products in their portfolio, thus competition and pricing pressures in the development and marketing of POC diagnostic devices is intense. There are a large number of multinational and regional competitors making investments in competing tec …
- 低浸透インクの世界市場予測（～2022年）：プロセス（グラビア印刷、フレキソ印刷、オフセット印刷、デジタル印刷）、需要先、地域別分析The low migration inks market is projected to reach USD 2.72 Billion by 2022 from USD 1.82 Billion in 2017, at a CAGR of 8.4% between 2017 and 2022. Migration of inks is a major issue in applications such as food, beverages, and cosmetics. Inks with high molecular weight are used for printing and labeling to avoid contamination in these products. Inks with high molecular weight using selected comp …
- Mucopolysaccharidosis I (MPS I) (Hurler Syndrome)：グローバル臨床試験動向（2014年上半期）Mucopolysaccharidosis I (MPS I) (Hurler Syndrome) Global Clinical Trials Review, H1, 2014 Summary GlobalData's clinical trial report, “Mucopolysaccharidosis I (MPS I) (Hurler Syndrome) Global Clinical Trials Review, H1, 2014" provides data on the Mucopolysaccharidosis I (MPS I) (Hurler Syndrome) clinical trial scenario. This report provides elemental information and data relating to the clinical t …
- アルミニウムの世界市場The economic crisis of 2008 caused a sharp decline in the demand for aluminium worldwide. As a result of the lower demand, the market became oversupplied, which pushed the prices down. Excessive warehousing of aluminium is a result of this oversupply, with an estimated 5.5 million tonnes currently stored only in London Metal Exchange (LME). Previous years have seen continuous volatility in alumini …
- バイオマスボイラーの世界市場2016-2020About Biomass Boiler A biomass boiler is used to generate heat or power from biomass, with less impact on the environment than conventional fuel. Heating and cooling account for almost half of the world's energy consumption. This requirement is fulfilled using conventional sources such as electricity, which is generated from fossil fuels. Power generation from fossil fuels results in the emission …
- 発電業界のM&A及び投資動向（月別）：January 2013Power Monthly Deal Analysis - January 2013: M&A and Investment Trends Summary GlobalData's “Power Monthly Deal Analysis - January 2013: M&A and Investment Trends” report is an essential source of data and trend analysis on the mergers and acquisitions (M&As) and financings in the power industry. The report provides detailed information on M&As, equity/debt offerings, private equity, venture financ …
- 世界の変更・構成管理ソフトウェア市場動向（2012-2016）TechNavio's analysts forecast the Global Change and Configuration Management Software market to grow at a CAGR of 6.31 percent over the period 2012-2016. One of the key factors contributing to this market growth is the need to adhere to regulatory compliances. The Global Change and Configuration Management Software market has also been witnessing increased adoption of cloud-based solutions. Howeve …
- 医療機器業界のM&A及び投資動向（年別）：2012Medical Equipment Annual Deals Analysis: M&A and Investments Trends - 2012 Summary GlobalData's “Medical Equipment Annual Deals Analysis: M&A and Investments Trends - 2012” report is an essential source of data and trend analysis on mergers and acquisitions (M&A) and financing in the medical equipment market. The report provides detailed information on M&A, equity/debt offerings, private equity (P …
- 急性リンパ性白血病/急性リンパ芽球性白血病治療薬の世界市場[Global Acute Lymphocytic Leukemia Market 2015-2019] Covering: An in-depth study of the acute lymphocytic leukemia market and segmentation by route of administration (oral and parenteral), by type of molecules (biologics and small molecules), and by geography (the Americas, EMEA, and APAC). The report also presents a detailed analysis of the top companies operating in the market, including Amgen, …
- 遺伝子治療の世界市場：ベクター種類別（ウイルスベクター、非ウイルスベクター）、遺伝子種類別（抗原、サイトカイン、腫瘍抑制因子、自殺、欠乏、成長因子、受容体、その他）、用途別（腫瘍性疾患、希少疾患、心血管疾患、神経疾患、感染症、その他）The global gene therapy market was valued at $393.35 million in 2018, and is estimated to reach $6,205.85 million by 2026, registering a CAGR of 34.8% from 2019 to 2026. Gene therapy is a technique that involves the delivery of nucleic acid polymers into a patient’s cells as a drug to treat diseases. It fixes a genetic problem at its source. The process involves modifying the protein either to cha …
- グローバル自動音声認識市場：Global Automatic Speech Recognition Market 2014-2018TechNavio's analysts forecast the Global Automatic Speech Recognition market to grow at a CAGR of 16.28 percent over the period 2013-2018. One of the key factors contributing to this market growth is the increasing demand for speech-based biometrics. The Global automatic Speech Recognition market has also been witnessing the increased use of voice passwords. However, the issues with accuracy could …
